Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AmnioFix for Neurovascular Bundle Protection in RARP
NCT02645591Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2016
- Primary completion
- Nov 2019
- Modality
- Implantable Devices, Implantable Hydrogels, Tissue Cells
01
Overview
Phase 2, randomised, single-blind trial of AmnioFix in erectile dysfunction (ED) and urinary incontinence (UI) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Reducing Neurovascular Bundle Inflammation in Prostate Cancer Patients Undergoing Nerve Sparing Robotic Assisted Laparoscopic Radical Prostatectomy (RARP) at 3 months. Planned start Nov 2016; status: withdrawn.
02
Drugs
AmnioFix
03
Conditions
erectile dysfunction (ED)urinary incontinence (UI)
Beyond the preview
Go deeper on NCT02645591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02645591.